Clinical trialNCT05334368RecruitingPhase 3Interventional

Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

SponsorGlaxoSmithKlineEnrollment123Hypereosinophilic Syndrome

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

GSK Clinical Trials
GlaxoSmithKline
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

91 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Gsk Investigational Site
Buenos Aires, Argentina
Anahí Yañez
Recruiting
Gsk Investigational Site
Florida, Argentina
Miguel Angel A Bergna
Recruiting
Gsk Investigational Site
La Plata, Argentina
Sebastian Juan Magri
Recruiting
Gsk Investigational Site
Mar del Plata, Argentina
Luis Wehbe
Recruiting
Gsk Investigational Site
Quilmes, Argentina
Marcelo José Fernández
Recruiting

Australia

Gsk Investigational Site
Garran, Australian Capital Territory, Australia
Completed

Belgium

Gsk Investigational Site
Brussels, Belgium
Florence Roufosse
Recruiting

Brazil

Gsk Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
Laura Fogliatto
Recruiting
Gsk Investigational Site
Blumenau, Brazil
Marina Lima
Recruiting
Gsk Investigational Site
Rio de Janeiro, Brazil
Solange Valle
Recruiting
Gsk Investigational Site
Sorocaba, Brazil
Martti Anton Antila
Recruiting

Canada

Gsk Investigational Site
Ottawa, Ontario, Canada
Timothy Olynych
Recruiting
Gsk Investigational Site
Toronto, Ontario, Canada
Hassan Sibai
Recruiting

China

Gsk Investigational Site
Beijing, China
Daobin Zhou
Recruiting
Gsk Investigational Site
Changsha, China
Yajing Xu
Recruiting
Gsk Investigational Site
Guangzhou, China
Xin Du
Recruiting
Gsk Investigational Site
Guangzhou, China
Na Xu
Recruiting
Gsk Investigational Site
Harbin, China
Jun Ma
Recruiting
Gsk Investigational Site
Nanchang, China
Fei Li
Recruiting
Gsk Investigational Site
Shanghai, China
Junmin Li
Recruiting
Gsk Investigational Site
Suzhou, China
Suning Chen
Recruiting
Gsk Investigational Site
Wuhan, China
Yu Hu
Recruiting

Czechia

Gsk Investigational Site
Brno-Bohunice, Czechia
Michael Doubek
Recruiting
Gsk Investigational Site
Hradec Králové, Czechia
Irena Krcmova
Recruiting
Gsk Investigational Site
Prague, Czechia
Lucie Heribanova
Recruiting
Gsk Investigational Site
Ústí nad Labem, Czechia
Dalibor Jilek
Recruiting

Denmark

Gsk Investigational Site
Odense C, Denmark
Gunhild Nynke Thomsen
Recruiting

Germany

Gsk Investigational Site
Bad Bramstedt, Germany
Ina Kötter
Recruiting
Gsk Investigational Site
Mannheim, Germany
Juliana Schwaab
Recruiting

Greece

Gsk Investigational Site
Athens, Greece
Maria Pagoni
Recruiting
Gsk Investigational Site
Rio Patras, Greece
Withdrawn

Hong Kong

Gsk Investigational Site
Pokfulam, Hong Kong
Yok Lam Kwong
Recruiting

Israel

Gsk Investigational Site
Ramat Gan, Israel
Nancy Agmon Levin
Recruiting
Gsk Investigational Site
Tel Aviv, Israel
David Hagin
Recruiting

Italy

Gsk Investigational Site
Bologna, Italy
Cristina Papayannidis
Recruiting
Gsk Investigational Site
Catania, Italy
Alessandra Romano
Recruiting
Gsk Investigational Site
Milan, Italy
Lorenzo Dagna
Recruiting
Gsk Investigational Site
Naples, Italy
Fabrizio Pane
Recruiting
Gsk Investigational Site
Novara, Italy
Andrea Patriarca
Recruiting
Gsk Investigational Site
Pavia, Italy
Chiara Elena
Recruiting

51 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 6 Sept 2022
Primary completion: 19 Dec 2028
Completion: 19 Dec 2028
Last update posted: 25 Nov 2025
Registered enrollment: 123
Registry id: NCT05334368

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.